We are excited to announce our partnership with Ra Pharma for RA101495-02.202: A Phase 2 Study of Zilucoplan in...
Tag Archive for: clinical trials
Second Annual “A Day of Remembrance” a video event to honor and remember those we have lost with myositis....
An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for Sporadic Inclusion Body Myositis Video
Myositis Support, , Featured, Inclusion Body Myositis (IBM)The ongoing Arimoclomol Clinical Trial for sIBM continues to generate a lot of questions from our community. As part...
An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for sIBM
Myositis Support, , Inclusion Body Myositis (IBM), VideoWatch "An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for sIBM" with Dr. Mazen Dimachkie,...
Learn about how clinical trials work in this educational and interactive video session led by Lindsey Wahlstrom-Edwards, Head of...
DETERMINE - a Phase 3 trial designed to evaluate the efficacy and safety of lenabasum for the treatment of adults...
Corbus launches DETERMINE, a Phase 3 trial of lenabasum for the treatment of dermatomyositis
Myositis Support, , Dermatomyositis, Featured, NewsNew locations announced July 9, 2019. DETERMINE is a double-blind, placebo-controlled 1-year study designed to test the efficacy and...
MSU and Orphazyme: Working together for a treatment for inclusion body myositis
Myositis Support, , Featured, NewsUpdated April 23, 2019 - Study is fully enrolled. One of our goals is to provide inclusion body...
Lenabasum for dermatomyositis receives orphan designation in the European Union
Myositis Support, , NewsToday, Corbus Pharmaceuticals announced that the European Commission has approved orphan designation for lenabasum in the treatment of dermatomyositis...
New Study for Patients with Inclusion Body Myositis (IBM) at Yale
Myositis Support, , Inclusion Body Myositis (IBM)We would like to let you know about a clinical research study that is available for patients diagnosed with...
Corbus Pharmaceuticals announced today that they will proceed with a Phase 3 clinical trial to evaluate the efficacy and...
Corbus Pharmaceuticals will host Jerry Williams, the Founder and President of MSU, Heather Spadaccini, Jerry’s friend and part-time caregiver,...
MSU, a patient-centered 501(c)(3) nonprofit organization, is proud to announce a partnership with Antidote Technologies, a digital health company...
Orphazyme formally assumes the sponsorship of Phase II/III arimoclomol trial for sIBM
Myositis Support, , Inclusion Body Myositis (IBM), NewsOn December 14, 2017, Orphazyme A/S, University of Kansas Medical Center, and UCL announced that Orphazyme formally assumes the...
FDA grants Orphazyme drug arimoclomol orphan drug designation in the U.S.
Myositis Support, , Inclusion Body Myositis (IBM), NewsOrphazyme A/S, a Danish biotech company with a late-stage orphan drug pipeline, today announced that the U.S. Food and...
Investigators are seeking people with dermatomyositis to participate in a phase 2 clinical trial of the experimental drug IMO-8400....
Clinical trials for Myositis and other rare diseases is an essential step to finding safe and effective treatments. There...